888-969-2592
Kalkine 0
countryflagCA

Knight Therapeutics Inc.

Healthcare CA GUD

5.82CAD
0.07(1.22%)

Last update at 2025-06-30T18:41:00Z

Day Range

5.755.83
LowHigh

52 Week Range

5.086.45
LowHigh

Fundamentals

  • Previous Close 5.75
  • Market Cap600.75M
  • Volume9761
  • P/E Ratio60.30
  • Dividend Yield-%
  • EBITDA46.76M
  • Revenue TTM372.78M
  • Revenue Per Share TTM3.70
  • Gross Profit TTM 167.57M
  • Diluted EPS TTM0.10

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -21.98800M -43.96000M 6.69M 32.09M 22.78M
Minority interest - - - - -
Net income -16.83500M -29.89200M 15.68M 31.76M 14.52M
Selling general administrative 37.41M 40.15M 37.16M 38.84M 24.46M
Selling and marketing expenses 46.28M 48.47M 37.22M 35.59M 7.79M
Gross profit 107.61M 138.06M 115.41M 81.69M 26.92M
Reconciled depreciation - - - - -
Ebit 6.43M -2.40300M -5.32200M -3.43700M 13.99M
Ebitda 56.82M 60.22M 42.59M 28.64M 18.26M
Depreciation and amortization 50.40M 62.62M 47.91M 32.08M 4.27M
Non operating income net other - - - - -
Operating income 6.43M -2.40300M -5.32200M -3.43700M 13.99M
Other operating expenses 321.77M 310.62M 256.31M 229.52M 60.12M
Interest expense 12.49M 6.60M 3.62M 3.40M 1.01M
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -5.15300M -14.06800M -8.98500M 0.33M 4.75M
Total revenue 328.20M 293.56M 243.48M 199.52M 47.46M
Total operating expenses 101.19M 155.12M 128.24M 111.69M 39.58M
Cost of revenue 220.59M 155.50M 128.07M 117.83M 20.54M
Total other income expense net -28.41400M -41.55700M 12.01M 35.52M 8.80M
Discontinued operations - - - - -
Net income from continuing ops - - - - -
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 945.49M 1054.84M 991.89M 1039.68M 1305.30M
Intangible assets 289.96M 338.78M 350.30M 156.55M 173.37M
Earning assets - - - - -
Other current assets 20.63M 1.70M 4.51M 4.75M 85.01M
Total liab 198.62M 228.98M 149.87M 153.44M 390.20M
Total stockholder equity 746.87M 825.86M 842.02M 886.24M 810.73M
Deferred long term liab - - - - -
Other current liab 7.90M 15.01M 11.72M 15.90M 225.63M
Common stock 540.05M 599.05M 628.85M 694.35M 723.83M
Capital stock - 599.05M 628.85M 694.35M 723.83M
Retained earnings 150.89M 161.75M 191.65M 174.54M 52.25M
Other liab - - 31.89M 36.83M 29.56M
Good will 79.84M 82.27M 75.40M 77.72M 88.26M
Other assets - 15.60M 57.05M 75.49M 151.97M
Cash 58.76M 71.68M 85.96M 229.59M 169.27M
Cash and equivalents - 0.30M 9.03M 2.58M 5.34M
Total current liabilities 114.03M 141.32M 105.30M 114.06M 350.80M
Current deferred revenue 1.18M - - 14.61M 39.85M
Net debt 10.33M 6.02M -45.00500M -173.40400M -107.08900M
Short term debt 19.58M 20.25M 28.28M 53.65M 52.34M
Short long term debt - 17.67M 26.66M 51.77M 50.56M
Short long term debt total 69.09M 77.70M 40.96M 56.19M 62.18M
Other stockholder equity 25.99M 23.78M 21.89M 18.85M 17.25M
Property plant equipment - 22.63M 29.94M 26.16M 29.05M
Total current assets 365.12M 395.62M 307.32M 554.64M 698.22M
Long term investments - 158.02M 178.95M 174.84M 259.72M
Net tangible assets - - 416.32M 651.97M 549.10M
Short term investments 95.66M 119.54M 77.03M 181.75M 261.35M
Net receivables 98.23M 110.20M 67.41M 82.04M 111.73M
Long term debt - 52.40M 9.27M 0.00000M 5.02M
Inventory 91.83M 92.49M 72.40M 56.51M 70.87M
Accounts payable 85.37M 106.06M 65.31M 44.51M 72.83M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 29.95M 41.27M -0.37600M -1.50300M 17.41M
Additional paid in capital - - - - -
Common stock total equity - - - 694.35M 723.83M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 7.77M 48.20M 47.93M 47.33M 52.69M
Deferred long term asset charges - - - - -
Non current assets total 580.38M 659.22M 684.57M 485.04M 607.08M
Capital lease obligations - 7.63M 5.03M 4.42M 6.60M
Long term debt total - 57.45M 12.68M 2.54M 9.83M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments - - - - -
Change to liabilities - - - - -
Total cashflows from investing activities - - - - -
Net borrowings - - - - -
Total cash from financing activities -71.12300M 1.76M -78.31000M -29.23300M -62.79500M
Change to operating activities - - - - -
Net income -16.83500M -29.89200M 15.68M 31.76M 18.03M
Change in cash -12.91800M -14.28400M -143.62900M 55.32M -70.51700M
Begin period cash flow 71.68M 85.96M 229.59M 174.27M 244.78M
End period cash flow 58.76M 71.68M 85.96M 229.59M 174.27M
Total cash from operating activities 28.49M 40.48M 44.62M -12.20500M 4.60M
Issuance of capital stock - - - - -
Depreciation 50.40M 62.62M 47.91M 32.08M 4.27M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory 0.70M -11.42800M -17.18800M 9.71M 8.15M
Change to account receivables 5.58M -26.41800M 8.59M 20.11M -10.40300M
Sale purchase of stock -53.47900M -30.06900M -64.41500M -36.78700M -54.83800M
Other cashflows from financing activities -2.85100M 52.12M 9.72M 25.41M 0.66M
Change to netincome - - - - -
Capital expenditures 9.96M 25.82M 224.18M 20.67M 2.95M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -28.01300M -9.98900M 0.63M -21.60700M -12.19900M
Stock based compensation 2.33M 1.89M 3.04M 1.95M 2.14M
Other non cash items 29.74M 32.98M -15.00800M -54.37100M -8.55800M
Free cash flow 18.54M 14.66M -179.56500M -32.87300M 1.65M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GUD
Knight Therapeutics Inc.		 0.07 1.22% 5.82 60.30 80.65 1.61 0.76 1.27 6.84
BHC
Bausch Health Companies Inc		 0.26 2.94% 9.09 - 1.69 0.32 18.74 2.33 8.07
CRON
Cronos Group Inc		 -0.02 0.77% 2.58 13.68 - 8.04 0.67 0.02 -1.9458
CURA
Curaleaf Holdings Inc.		 0.03 2.27% 1.12 - 138.89 0.62 0.72 1.00 5.90
TLRY
Tilray Inc		 0.01 1.85% 0.55 - 1000.00 0.66 0.14 0.56 -2.299

Reports Covered

Stock Research & News

View All

Profile

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, the company finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.

Knight Therapeutics Inc.

3400 de Maisonneuve Blvd. W., Montreal, QC, Canada, H3Z 3B8

Key Executives

Name Title Year Born
Mr. Jonathan Ross Goodman B.A., BA, L.L.B., LLB, M.B.A., MBA Exec. Chairman 1969
Ms. Samira Sakhia BCom, CA, CPA, MBA Pres, CEO & Director 1968
Mr. Arvind Utchanah Chief Financial Officer NA
Ms. Amal Khouri B.Sc., M.B.A. Chief Bus. Officer NA
Mr. Jeff Martens Global VP Commercial NA
Mr. Leopoldo Bosano Vice-Pres of Manufacturing & Operations NA
Ms. Daniela Marino Global VP of Legal & Compliance NA
Ms. Susan Caroline Emblem Global VP of HR NA
Ms. Jody Engel Sr. Director of Bus. Devel. NA
Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A. Executive Chairman 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.